This cross-sectional study investigates the prevalence of prenatal exposure to teratogenic medications and of prenatal care initiation across gestational weeks relative to common timing cutoffs for legal abortion. https://t.co/vrmN0A8gpk
Awesome faculty, staff and students, great resources and a brand-new building. Happy to chat about this great opportunity (https://t.co/21cOWgNH1q). Please spread the word.
Join us for the upcoming live webcast with @cmeoutfitters to support the mycophenolate REMS implementation. Tune in 11/08 at 6:30 PM ET & earn 1 free #CME/CE credit. There is a need to enhance prevention of prenatal exposure https://t.co/qX1aErn4zG.
The two newest PhDs delivered to science! Undoubtedly the most rewarding aspect of my work. Congratulations to @Amir_Sarayani and @thuynthai You both will be fantastic!
Very important course in the Pharmacoepidemiology menu: if one looks forward to make exposure assignments there is a chance one created bias. So easy to do...
@_MiguelHernan /12
Paper #8: On the perils of immortal time bias and other time-related biases in pharmacoepidemiology - Suissa and Dell’Aniello review time-related biases and demonstrate their impact using a cohort of patients treated for COPD.
https://t.co/VgHI5y7hp5
/9
Paper #5: What aspects of an association should you examine before making conjectures about the possibility that this association may in fact reflect a causal mechanism? A short (yet clever and timeless!) classic.
https://t.co/pUy3Ybnd1I
We wrote this paper in December (before any emerging safety concerns). Updating it during the review process with that information was really troubling. Noteworthy, good old spontaneous reporting found safety issues first, not our sophisticated real-world data. A lot to do...
New publication by #almutwinterste1 and colleagues on the global #COVID19#vaccines safety infrastructure.
Global covid-19 vaccine rollout and safety surveillance—how to keep pace https://t.co/P4EQSQCqnC
An example for this would be the "and there could be residual confounding and therefore my findings may be meaningless" disclaimer. Address residual confounding instead? Could it explain your results? Under what circumstances?
@ken_rothman /7
Paper #3: If your goal is to establish causality, don't hide it! In this paper, @_MiguelHernan makes a strong and important plea for more transparency and honesty in observational research.
https://t.co/Qwih9ckEfx
Trying to figure out which risk mitigation approaches actually work - one study at a time. FDA, we need more on this to make evidence-based policy decisions.
.@US_FDA took unusual action in removing uncomplicated infections from fluoroquinolones’ labeling indications. A @UF study in @JAMAInternalMed shows it helped reduce the antibiotics’ ubiquitous use, which has harmful side effects. @AlmutWinterste1@UFCoDES https://t.co/QEDklau7JE